Mesalazine


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult: PO Ulcerative colitis Dose is dependent on product used. Asacol 400 mg tab, Ipocol tab Acute attack: Initial: 2.4 g/day in divided doses. Maintenance of remission: 1.2-2.4 g/day in divided doses. Asacol 800 mg tab Mild acute exacerbations: 2.4 g/day in divided doses. Moderate acute exacerbations: 4.8 g/day in divided doses. Maintenance of remission: Up to 2.4 g/day in divided doses. Mezavant Acute attack: Initial: 2.4-4.8 g once daily. Maintenance of remission: 2.4 g once daily. Pentasa tab Acute attack: Initial: Up to 4 g/day in 2 or 3 divided doses. Maintenance of remission: Initial: 2 g once daily, then adjusted individually. Pentasa granule Acute attack: Initial: Up to 4 g/day in 2-4 divided doses. Maintenance of remission: 2 g once daily. Salofalk Acute attack: As tab: Initial: 1.5-3 g/day in 3 divided doses. As granule: Initial: 1.5-3 g once daily or in 3 divided doses. Maintenance of remission: 1.5 g/day in 3 divided doses. Rectal Ulcerative proctitis Dose is dependent on preparation and brand used. Asacol supp 0.75-1.5 g/day in divided doses. Asacol foam enema Rectosigmoid region: 1 g/day for 4-6 wk. Descending colon: 2 g/day for 4-6 wk. Pentasa supp or susp enema Acute treatment: 1 g/day for 2-4 wk. Maintenance: 1 g/day. Salofalk supp 0.5-1 g given 2 or 3 times/day. Salofalk foam/susp enema 2 g/day at bedtime.
Contraindications
Hypersensitivity to salicylates. Severe hepatic or renal (GFR <20 mL/min) impairment.
Special Precautions
Patient w/ conditions predisposing to myocarditis or pericarditis, active peptic ulceration, history of sulfasalazine hypersensitivity. Mild to moderate renal or hepatic impairment. Pregnancy and lactation. Patient Counselling This drug may cause nausea, if affected, do not drive or operate machinery. Monitoring Parameters Monitor renal and hepatic function (i.e. ALT, CBC).
Adverse Reactions
Headache, dizziness, GI disturbances (e.g. diarrhoea, nausea, vomiting, abdominal pain, flatulence), Rarely, blood dyscrasia (e.g. agranulocytosis, aplastic anaemia, leucopenia, methaemoglobinaemia, neutropenia, thrombocytopenia), myocarditis, pericarditis, pancreatitis, interstitial nephritis, nephritic syndrome, allergic lung reaction, increased liver enzyme values, hepatitis, lupus-like syndrome, skin reactions, alopecia, peripheral neuropathy, arthralgia, myalgia, hypersensitivity reactions, exacerbation of symptoms of colitis.
Potentially Fatal: Induced pericarditis.
Drug Interactions
Drugs that lower colonic pH (e.g. lactulose) may prevent the release of mesalazine. Increased risk of haematologic toxicity w/ azathioprine or mercaptopurine. Increased risk of nephrotoxicity w/ nephrotoxic drugs (e.g. NSAIDs, azathioprine). May decrease GI absorption of digoxin.
ATC Classification
A07EC02 - mesalazine ; Belongs to the class of aminosalicylic acid and similar antiinflammatory. Used in the treatment of intestinal inflammation.
Disclaimer: This information is independently developed by CIMS based on mesalazine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in